Chemomab Therapeutics to Merge with Scipher Medicine in Reverse Acquisition, Valued at $150M Pre-PIPE
CMMB has more than doubled off its 52-week low of $1.35 on elevated volume (4.0× avg).
Summary
Chemomab Therapeutics has entered into a definitive merger agreement with Scipher Medicine Corporation, effectively a reverse acquisition where Chemomab shareholders will own 32% of the combined company, valued at $150 million pre-PIPE. The deal includes a $30 million PIPE investment and shifts the strategic focus to advancing nebokitug for rheumatoid arthritis.
Key Events · M&A and Partnerships · CMMB
-
Definitive Merger Agreement
Chemomab Therapeutics Ltd. has entered into a definitive merger agreement with Scipher Medicine Corporation, with the combined entity to be named Scipher Medicine Corporation and trade under the ticker 'SCIP'.
-
Ownership Structure & Valuation
Pre-Merger Chemomab equity holders are expected to own approximately 32% of the combined company, while Scipher equity holders will own approximately 68%, on a fully-diluted basis. The combined company is valued at $150 million before the concurrent PIPE investment.
-
Concurrent PIPE Investment
A syndicate of current Scipher investors has committed to a new financing totaling at least $30 million in gross cash proceeds, providing a cash runway into H2 2028 for the combined company.
-
Strategic Focus Shift
The combined company will focus on advancing nebokitug, a first-in-class anti-CCL24 antibody, into a Phase 2 trial for rheumatoid arthritis (RA) by leveraging Scipher's AI Network Medicine platform, with topline results expected in H1 2028.
Analysis · CMMB · Life Sciences
This definitive merger agreement represents a transformational event for Chemomab Therapeutics. The company is effectively being acquired in a reverse merger, with existing Chemomab shareholders receiving 32% ownership of the combined entity, which is valued at $150 million before a concurrent $30 million PIPE investment. This implied valuation for Chemomab shareholders (approximately $48 million) is significantly higher than the company's current market capitalization, offering a substantial premium. The transaction also secures a $30 million capital infusion, extending the combined company's cash runway into the second half of 2028, addressing critical liquidity needs. The strategic shift to focus on advancing nebokitug for rheumatoid arthritis, leveraging Scipher's AI platform, provides a new direction and potential for value creation, while CVRs offer additional upside for Chemomab's legacy assets. This fundamentally alters the investment thesis for Chemomab.
At the time of this filing, CMMB was trading at $2.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.9M. The 52-week trading range was $1.35 to $4.92. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.